Jacobs was awarded an engineering, procurement, and construction management contract with Spark Therapeutics, Inc. (Spark) to build its Gene Therapy Innovation Center in the University City neighborhood of West Philadelphia . When complete, the multi-story facility will serve as a global center of excellence for gene therapy manufacturing and advance the science of gene therapy.
According to Spark, the first phase of the project includes an initial investment of $575 million, and the planned 500,000 square foot facility nearly doubles the company’s physical footprint in Philadelphia. The installation is expected to be completed in 2026.
“Our goal is to build an innovative facility that supports Spark’s mission to advance science,” said Koti Vadlamudi, senior vice president of Jacobs Advanced Facilities. “It will also be the first gene therapy manufacturing facility of its size in Philadelphia. We’re ready to support Spark’s vision of a world where no life is limited by genetic disease.
Jacobs has provided solutions to more than 30 customers in the cell and gene therapy market on projects involving large-scale launch and production facilities with multiple modalities.
Jacobs Engineering Group Inc. published this content on June 16, 2022 and is solely responsible for the information contained therein. Distributed by Audienceunedited and unmodified, on Jun 16, 2022 4:12:03 PM UTC.